Alterity Therapeutics (ASX:ATH) has announced that the last patient in its ATH434-201 Phase 2 trial in early-stage multiple system atrophy has completed the study. …
Alterity Therapeutics completes last patient visit in ATH434-201 trial in multiple system atrophy
December 4, 2024 Australian Biotech
Latest Video
New Stories
-
AusBiotech takes 15-year refund limit fight to the Senate as R&D tax bill lands
October 28, 2026 - - Latest News -
The stakes are very high on access in a contested budget environment
October 28, 2026 - - Latest News -
Managing an agreement negotiation as a 'prisoner of circumstance'
October 28, 2026 - - Latest News -
Lung scarring killing 11 Australians a day, with one in five cases traced to work
October 28, 2026 - - Latest News -
MSAC suggests minister skip HTA and make policy fix to ensure access to this technology
October 28, 2026 - - Latest News -
Company rebates fall for the first time in years, lifting net PBS costs
October 27, 2026 - - Latest News -
Access delayed - the stakes are high for the industry's next agreements
October 27, 2026 - - Latest News